Last updated: June 14, 2026

CYLERT (pemoline) market dynamics and financial trajectory: sales trend, payer pull, regulatory headwinds, and how exclusivity affects value

CYLERT (pemoline) is a legacy CNS stimulant whose US commercial footprint has been structurally constrained by safety-driven withdrawal. In the US, pemoline’s market position is not shaped primarily by near-term patent expiry or competitive launches. It is shaped by regulatory and supply realities that limit prescribing and reduce likelihood of sustained, high-volume revenue. The financial trajectory is therefore dominated by contraction in patient use rather than by life-cycle “share shifts” around generics.

Why did CYLERT sales decline and how did FDA actions reshape the market?

Executive answer: US CYLERT is functionally a shrinking/low-visibility market due to safety restrictions and regulatory pressure that reduced mainstream pediatric ADHD adoption. Revenue has followed declining demand and constrained supply rather than a typical “patent vs generic” cycle.

What regulatory events drove demand erosion

Pemoline (CYLERT) has faced prolonged scrutiny tied to serious liver injury, including reports of hepatic failure. Over time, FDA actions and labeling restrictions reduced its use, particularly versus safer stimulant alternatives (methylphenidate and amphetamine products).

Market impact channels:

Prescriber behavior: Hepatotoxicity risk led clinicians to favor alternative stimulants and non-stimulants.
Payer utilization management: Higher-risk profiles tend to trigger step therapy, prior authorization, and tighter coverage.
Patient switching and discontinuation: Once safer options are available, chronic stimulant therapy is readily substituted.
Supply constraints: Even when supply exists, a smaller eligible patient base reduces purchasing predictability.

Is CYLERT still a meaningful US commercial product

In practical market terms, CYLERT functions as a low-demand, legacy therapy rather than a growth stimulant franchise. That matters for financial modeling: the “unit volume” tail is thin, and the price environment becomes less about competitive generics and more about whether supply and distribution persist for low-utilization SKUs.

What is the competitive landscape for CYLERT and how do safer ADHD stimulants change pricing power?

Executive answer: CYLERT’s competitive set is less about “same molecule” challengers and more about the broader ADHD stimulant market. Safer stimulant alternatives compress any achievable price premium.

Substitution risk by drug class

Even without a full replacement product at the same molecule level, substitution risk is high because ADHD therapy is frequently switched within and across stimulant classes.

Key competitor clusters in ADHD include:

Methylphenidate immediate- and extended-release products
Amphetamine immediate- and extended-release products
Non-stimulants (atomoxetine, guanfacine ER, clonidine ER) depending on patient risk profile

Pricing power implication: When alternatives are plentiful, payers can steer usage through coverage criteria. That reduces the economic value of any single legacy molecule, especially one encumbered by safety.

How do patents and exclusivity timelines affect CYLERT revenue potential?

Executive answer: CYLERT’s financial trajectory is dominated by regulatory and demand constraints, not by exclusivity. Even when patents exist historically, they do not create the same commercial uplift as in safety-neutral products because the addressable patient base contracts.

Typical lifecycle pattern vs CYLERT reality

In standard CNS franchises, revenue is supported by:

composition-of-matter and formulation exclusivity
later-expiring patents on dosing regimens, controlled release, and manufacturing
brand-to-generic timing and generic entry sequencing

For CYLERT, demand erosion reduces the revenue leverage of delayed generic competition. A brand can lose commercial relevance long before all IP expires if prescribers and payers move away.

What Orange Book status and generic entry risks exist for CYLERT?

Executive answer: For an older, safety-restricted product, generic entry risk is less a near-term event and more an established market reality. The more binding question is whether the product remains sufficiently covered and supplied to sustain meaningful sales.

How to think about Paragraph IV and exclusivity

Paragraph IV frameworks matter mainly when a brand still maintains meaningful sales at risk of erosion.
For CYLERT, regulatory-driven utilization decline reduces the “value-at-risk” from generic entry.
The practical risk profile becomes: supply continuity, distribution economics, and payer restrictions.

(If Orange Book listings are required for a formal “at-risk launch” view, they must be tied to specific CYLERT NDCs and dosage forms. This market dynamic question is governed primarily by safety demand constraints.)

What formulations and dosing availability drive CYLERT commercial viability?

Executive answer: For low-demand legacy stimulants, commercial viability hinges on which NDCs are actively marketed, their packaging sizes, and whether discontinuations leave remaining patients dependent on inconsistent supply.

Formulation-level economics

In legacy products, revenue is concentrated in:

higher volume pack sizes where wholesalers keep safety stock
fewer dose strengths if prescribers reduce titration complexity
extended-release vs immediate-release availability (if any), though pemoline’s market has historically been dominated by older delivery formats

Financial implication: Sales can become lumpy and discontinuous if manufacturers withdraw specific strengths or if distribution networks adjust inventory.

Which companies historically marketed CYLERT and how do ownership changes affect financial reporting?

Executive answer: CYLERT is a legacy brand with ownership and marketing history that can fragment revenue across corporate reporting periods. Market-level performance is still governed by usage decline, but company-level trajectories can differ due to divestitures and rebranding.

How to interpret company financial statements

When modeling a legacy brand:

Brand-level gross sales may be reclassified into “other products” buckets.
Marketing rights and distribution agreements can shift from primary manufacturers to distributors.
Net sales can be strongly influenced by rebates and chargebacks that correlate with payer coverage decisions.

Net effect: Corporate revenue impact from CYLERT is usually limited versus multi-product ADHD portfolios.

What do payer and provider behaviors imply for CYLERT long-run demand?

Executive answer: For a safety-risk CNS stimulant, long-run demand tends to be constrained and stable only at a reduced ceiling. Demand is sustained by niche patient needs and prescriber familiarity, not by broad pediatric ADHD adoption.

Payer utilization management drivers

preferred drug lists favor lower hepatotoxicity risk
prior authorization requirements for legacy agents
quantity limits or step therapy policies

Provider behavior drivers

baseline liver monitoring burdens can reduce uptake
risk-benefit calculus shifts when alternative stimulants are effective
clinical guideline evolution favors safer options

Financial implication: Revenue decay rates can slow into a steady low-level “maintenance” period. Growth is unlikely absent major safety reversals or differentiated clinical positioning.

What is the likely revenue shape for CYLERT under a “decline-to-stability” model?

Executive answer: The financial trajectory is best represented as early steep decline followed by low-level stabilization, rather than late-cycle generic-driven collapse.

Typical decline-to-stability pattern for safety-constrained legacy brands

Years of utilization contraction driven by labeling risk and practice changes
Gradual market thinning as remaining prescribers discontinue use
Low but persistent demand for constrained cohorts
Limited upside from price due to payer push toward alternatives

How this differs from a patent cliff

Patent expiry triggers entry, but entry only matters if the brand still has meaningful volume.
In CYLERT’s case, the binding constraint is the reduced number of patients and the willingness of prescribers and payers to continue use.

How does CYLERT compare with modern ADHD franchises in market economics?

Executive answer: Modern ADHD franchises have high prescription velocity and broad payer coverage. CYLERT’s economics are instead constrained by risk perception and a smaller covered population, yielding low sales velocity and limited pricing leverage.

Key comparative metrics to expect

For CYLERT versus large ADHD brands:

lower TRx and fewer active prescribers
lower distribution scale and higher logistical inefficiency
less ability to defend price against substitution
higher sensitivity of sales to supply availability

Competitive positioning: CYLERT competes for residual niche patients rather than for mainstream market share.

What litigation, settlements, or withdrawal events affect CYLERT commercial trajectory?

Executive answer: For CYLERT, safety and regulatory pressure are the primary commercialization shapers. Litigation can influence market posture, but the dominant driver of revenue trajectory remains demand restriction.

How safety-driven market events translate to financial outcomes

label strengthening that tightens use
monitoring requirements increasing prescriber friction
discontinuations or limited supply altering patient continuity

Key Takeaways

CYLERT’s market dynamics are dominated by safety-driven demand erosion, not by a typical patent vs generic timeline.
Revenue trajectory follows a decline-to-low-level-stability pattern: shrinking addressable population, reduced pricing power, and dependence on ongoing supply and niche coverage.
Competitive pressure comes primarily from safer ADHD stimulants and non-stimulant alternatives, which increase substitution risk and limit payer tolerance for legacy high-risk agents.
Exclusivity and generic entry can be secondary for value-at-risk because the product’s sales base is structurally smaller.

FAQs

Is CYLERT still used for ADHD in the US, and what patient cohorts remain?
Use is largely niche, sustained by residual clinical selection and constrained by safety monitoring burdens.
Does CYLERT have meaningful pricing power versus methylphenidate and amphetamine products?
No. Payer steering toward safer alternatives typically compresses achievable net pricing.
What NDC or dosage forms drive the remaining CYLERT market?
Only currently marketed strengths with active distribution can generate revenue; discontinued strengths reduce the total addressable volume.
Do generic entry and ANDA filings materially impact CYLERT revenue?
They tend to be less material than regulatory utilization constraints, unless a still-meaningful sales base exists for specific NDCs.
What monitoring or label restrictions most affect CYLERT adoption?
Liver monitoring requirements and hepatotoxicity risk materially increase prescriber friction and reduce broad prescribing.

References (APA)

U.S. Food and Drug Administration. (n.d.). Drug Safety Communications and labeling information for pemoline (CYLERT). FDA.
U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). FDA.

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	45
Patent Applications:	4,384
DailyMed Link:	CYLERT at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	CYLERT	pemoline	TABLET, CHEWABLE;ORAL	017703-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbott	CYLERT	pemoline	TABLET;ORAL	016832-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbott	CYLERT	pemoline	TABLET;ORAL	016832-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

CYLERT Drug Patent Profile

Which patents cover Cylert, and when can generic versions of Cylert launch?

AI Deep Research

Questions you can ask:

Summary for CYLERT

US Patents and Regulatory Information for CYLERT